Antithrombotic activity of a new P2Y1 receptor antagonist, substance Sbt-119, on experimental models of thromboses in rats.
Antithrombotic properties of a new P2Y1 receptor antagonist N-[(1-morpholinopropyl-amino)- carbonyl-2-(1-ethyl-1H-indole-3-yl)-vinyl]-4-methylphenyl-amide hydrochloride, substance Sbt-119, and reference drug ticlopidine were studied on experimental models of arterial and systemic thromboses. Substance Sbt-119 was 39.9% (p<0.05) more potent than ticlopidine in producing the antithrombotic effect. Moreover, substance Sbt-119 was shown to increase the survival rate of animals after systemic treatment with ADP (by 20%, p<0.0001). This substance decreased the number of mural thrombi and reduced the severity of hemodynamics disturbances in the organs during systemic thrombosis.
Volgograd State Medical University, Ministry of Health of the Russian Federation, Volgograd, Russia, dypharm@list.ru.
D S
DS
Yakovlev
A A
AA
Spasov
T M
TM
Bukatina
A V
AV
Smirnov
K F
KF
Suzdalev
D000284:Administration, Oral; D000818:Animals; D021461:Animals, Outbred Strains; D004353:Drug Evaluation, Preclinical; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D007211:Indoles / Q000008:administration & dosage*; D008168:Lung / Q000473:pathology; D008297:Male; D051379:Mice; D009025:Morpholines / Q000008:administration & dosage*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage*; D051381:Rats; D013927:Thrombosis / Q000188:drug therapy*; D013988:Ticlopidine / Q000494:pharmacology
D005343:Fibrinolytic Agents; D007211:Indoles; D009025:Morpholines; D058921:Purinergic P2Y Receptor Antagonists; C000599469:Sbt-119; D013988:Ticlopidine